drugset / Trial / NCT03766490
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
Unknown
66 enrolled
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University · collabChangzhou No.2 People's Hospital · collabChia Tai Tianqing Pharmaceutical Group Co., Ltd. · collabJiangyin People's Hospital · collabNantong University · collabSecond Affiliated Hospital of Soochow University · collabThe First People's Hospital of Changzhou · collab
NaSingle-groupOpen-labelTreatment
Summary
After the second-line treatment of patients with non-T790M mutations, chemotherapy with platinum-containing drugs was used, and chemotherapy-related toxicity was high. Studies have shown that bevacizumab combined with EGFR TKI have a good trend of benefit. This study is aimed to evaluate the efficacy and safety of Anlotinib Hydrochloride combined with first-generation EGFR TKIs as second-line treatment in advanced non-small cell lung cancer . The patients with IV non-small lung cancer have acquired resistance to prior first-generation EGFR TKIs and have non-T790M mutation.
Timeline
- Start
- 2019-03-30
- Primary completion
- 2019-12-20
- Completion
- 2020-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Gefitinib | Small molecule | 250 mg | Oral |
| Subject | Icotinib | Small molecule | 125 mg | Oral |